Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome

Genetics in Medicine

Volumn 14, Issue 12, 2012, Pages 977-982

  Wang, Daphne L ^a   Smith, Kelly B ^a,b   Esparza, Sonia ^a   Leigh, Fawn A ^a   Muzikansky, Alona ^a   Park, Elyse R ^a   Plotkin, Scott R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

emotional function; neurofibromatosis 1; neurofibromatosis 2; schwannomatosis; tumor suppressor syndromes

Indexed keywords

ADULT; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; EMOTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROFIBROMATOSIS; POPULATION; SCHWANNOMATOSIS; SELF ESTEEM; SELF REPORT; STATISTICAL SIGNIFICANCE; STRESS; SYMPTOM; VALIDATION STUDY;

ADULT; AFFECTIVE SYMPTOMS; DEPRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURILEMMOMA; NEUROFIBROMATOSES; NEUROFIBROMATOSIS 1; NEUROFIBROMATOSIS 2; PATIENT ACCEPTANCE OF HEALTH CARE; SKIN NEOPLASMS;

EID: 84868139004     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2012.85     Document Type: Article

References (39)

1. Evans DG, Ramsden RT, Shenton A, et al. What are the implications in individuals with unilateral vestibular schwannoma and other neurogenic tumors? J Neurosurg 2008;108:92-96.
2. Antinheimo J, Sankila R, Carpén O, Pukkala E, Sainio M, Jääskeläinen J. Population-based analysis of sporadic and type 2 neurofibromatosisassociated meningiomas and schwannomas. Neurology 2000;54:71-76. (Pubitemid 30038740)
3. Lu-Emerson C, Plotkin SR. The neurofibromatoses. Part 1: NF1. Rev Neurol Dis 2009;6:E47-E53.
4. Lu-Emerson C, Plotkin SR. The neurofibromatoses. Part 2: NF2 and schwannomatosis. Rev Neurol Dis 2009;6:E81-E86.
5. Wells KB, Golding JM, Burnam MA. Psychiatric disorder in a sample of the general population with and without chronic medical conditions. Am J Psychiatry 1988;145:976-981.
6. Page PZ, Page GP, Ecosse E, Korf BR, Leplege A, Wolkenstein P. Impact of neurofibromatosis 1 on Quality of Life: a cross-sectional study of 176 American cases. Am J Med Genet A 2006;140:1893-1898. (Pubitemid 44380075)
7. Kodra Y, Giustini S, Divona L, et al. Health-related quality of life in patients with neurofibromatosis type 1. A survey of 129 Italian patients. Dermatology 2009;218:215-220.
8. Wolkenstein P, Zeller J, Revuz J, Ecosse E, Leplège A. Quality-of-life impairment in neurofibromatosis type 1: a cross-sectional study of 128 cases. Arch Dermatol 2001;137:1421-1425. (Pubitemid 33064237)
9. Neary WJ, Hillier VF, Flute T, Stephens SD, Ramsden RT, Evans DG. The relationship between patients' perception of the effects of neurofibromatosis type 2 and the domains of the Short Form-36. Clin Otolaryngol 2010;35:291-299.
10. Samuelsson B, Samuelsson S. Neurofibromatosis in Gothenburg, Sweden. I. Background, study design and epidemiology. Neurofibromatosis 1989; 2:6-22. (Pubitemid 19147873)
11. Zöller ME, Rembeck B. A psychiatric 12-year follow-up of adult patients with neurofibromatosis type 1. J Psychiatr Res 1999;33:63-68. (Pubitemid 29052133)
12. Wolkenstein P, Zeller J, Revuz J, Ecosse E, Leplège A. Visibility of neurofibromatosis 1 and psychiatric morbidity. Arch Dermatol 2003;139:103-104.
13. Neary W, Stephens D, Ramsden RT, Evans DG. Psychosocial effects of neurofibromatosis type 2 (Part 1): general effects. Audiol Med 2006;4:202-210. (Pubitemid 350067129)
14. Katon WJ, Lin E, Russo J, Unutzer J. Increased medical costs of a populationbased sample of depressed elderly patients. Arch Gen Psychiatry 2003;60:897-903. (Pubitemid 37122308)
15. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measur 1977;1:385-401.
16. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav 1983;24:385-396.
17. Cohen S, Williamson G. Perceived stress in a probability sample of the United States. In: Spacapan S, Oskamp S (eds). The Social Psychology of Health: Claremont Symposium on Applied Social Psychology. Sage Publications: Newbury Park, CA, 1988, p. 31-67.
18. Rosenberg M. Society and the Adolescent Self-Image. Wesleyan University Press: Middletown, CT, 1989.
19. Sinclair SJ, Blais MA, Gansler DA, Sandberg E, Bistis K, LoCicero A. Psychometric properties of the Rosenberg Self-Esteem Scale: overall and across demographic groups living within the United States. Eval Health Prof 2010;33:56-80.
20. Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs AG. Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press: Palo Alto, CA, 1983.
21. Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated. Mult Scler 2009;15:385-392.
22. Goretti B, Portaccio E, Zipoli V, et al. Coping strategies, psychological variables and their relationship with quality of life in multiple sclerosis. Neurol Sci 2009;30:15-20.
23. Sundaram M, Kavookjian J, Patrick JH, Miller LA, Madhavan SS, Scott VG. Quality of life, health status and clinical outcomes in Type 2 diabetes patients. Qual Life Res 2007;16:165-177. (Pubitemid 46088351)
24. Surwit RS, van Tilburg MA, Zucker N, et al. Stress management improves longterm glycemic control in type 2 diabetes. Diabetes Care 2002;25:30-34. (Pubitemid 41070779)
25. Ried LD, Tueth MJ, Taylor MD, Sauer BC, Lopez LM, Pepine CJ. Depressive symptoms in coronary artery disease patients after hypertension treatment. Ann Pharmacother 2006;40:597-604.
26. Astin F, Jones K, Thompson DR. Prevalence and patterns of anxiety and depression in patients undergoing elective percutaneous transluminal coronary angioplasty. Heart Lung 2005;34:393-401. (Pubitemid 41735283)
27. de Graeff A, de Leeuw JR, Ros WJ, Hordijk GJ, Blijham GH, Winnubst JA. Sociodemographic factors and quality of life as prognostic indicators in head and neck cancer. Eur J Cancer 2001;37:332-339. (Pubitemid 32182321)
28. Fischer DJ, Villines D, Kim YO, Epstein JB, Wilkie DJ. Anxiety, depression, and pain: differences by primary cancer. Support Care Cancer 2010;18:801-810.
29. Giesler RB, Given B, Given CW, et al. Improving the quality of life of patients with prostate carcinoma: a randomized trial testing the efficacy of a nursedriven intervention. Cancer 2005;104:752-762. (Pubitemid 41113674)
30. Bodurka-Bevers D, Basen-Engquist K, Carmack CL, et al. Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol 2000;78(3 Pt 1):302-308.
31. Parker PA, Kudelka A, Basen-Engquist K, Kavanagh J, de Moor J, Cohen L. The associations between knowledge, CA125 preoccupation, and distress in women with epithelial ovarian cancer. Gynecol Oncol 2006;100:495-500. (Pubitemid 43246864)
32. Hann D, Winter K, Jacobsen P. Measurement of depressive symptoms in cancer patients: evaluation of the Center for Epidemiological Studies Depression Scale (CES-D). J Psychosom Res 1999;46:437-443. (Pubitemid 29277215)
33. Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol 1996;107:707-713. (Pubitemid 26371086)
34. American Academy of Otolaryngology-Head and Neck Surgery Foundation I. Committee on hearing and equilibrium guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma). Otolaryngol Head Neck Surg 1995;113:179-180.
35. House JW, Brackmann DE. Facial nerve grading system. Otolaryngol Head Neck Surg 1985;93:146-147. (Pubitemid 15064413)
36. Rumsey N, Clarke A, White P, Wyn-Williams M, Garlick W. Altered body image: appearance-related concerns of people with visible disfigurement. J Adv Nurs 2004;48:443-453. (Pubitemid 39540304)
37. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med 2003;163:2433-2445. (Pubitemid 37385786)
38. Katon W, Von Korff M, Lin E, et al. Distressed high utilizers of medical care. DSM-III-R diagnoses and treatment needs. Gen Hosp Psychiatry 1990;12:355-362. (Pubitemid 20359656)
39. Benjamin CM, Colley A, Donnai D, Kingston H, Harris R, Kerzin-Storrar L. Neurofibromatosis type 1 (NF1): knowledge, experience, and reproductive decisions of affected patients and families. J Med Genet 1993; 30:567-574. (Pubitemid 23225182)